Table 1 Baseline characteristics for both cohorts
|  | Training cohort (N = 115) | Validation cohort (N = 50) | p |
|---|---|---|---|
Sex/No. (%) | Â | Â | 0.583a |
  Male | 185 (80.4) | 77 (77.8) |  |
  Female | 45 (19.6) | 22 (22.2) |  |
Age | 57 (49–64) | 58 (51–63) | 0.284b |
Hepatitis B virus infection/No. (%) | Â | Â | 0.618a |
  Positive | 190 (82.6) | 84 (84.8) |  |
  Negative | 40 (17.4) | 15 (15.2) |  |
BCLC/No. (%) | Â | Â | 0.329a |
  Early stage (0-A) | 202 (87.8) | 83 (83.8) |  |
  Intermediate (B) | 28 (12.2) | 16 (16.2) |  |
Child’s class/No. (%) |  |  | 0.326a |
  A | 177 (77) | 81 (81.8) |  |
  B | 53 (23) | 18 (18.2) |  |
Largest tumor diameter (cm) | 5.4 (3.5–7.7) | 5.1 (3.1–7.6) | 0.430b |
Tumor number/(%) | Â | Â | 0.079a |
  Single | 197 (85.6) | 77 (77.8) |  |
  Multiple | 33 (14.3) | 22 (22.2) |  |
MVI/No. (%) | Â | Â | 0.462a |
  Positive | 202 (87.8) | 84 (84.8) |  |
  Negative | 28 (12.2) | 15 (15.2) |  |
AFP level (ng/mL) | Â | Â | 0.673a |
  ≤ 400 | 136 (59.1) | 61 (61.6) |  |
  > 400 | 94 (40.9) | 38 (38.3) |  |
PT (S) | 12.8 (12.3–13.5) | 12.7 (12.1–13.3) | 0.163b |
TBIL (µmol/L) | 13.9 (11.0-17.5) | 12.8 (10.9–17.3) | 0.156b |
Albumin (g/L) | 38.7 (35.8–40.8) | 38.4 (36.0-40.4) | 0.716b |
ALT(U/L) | 44 (28–64) | 43 (17–67) | 0.421b |
Rad-score | -8.11 (-8.57–7.71) | -8.25 (-8.66–7.77) | 0.217b |